The Fort Worth Press - Protagonist Announces Nomination of PN-881, a Potential Best-in-Class Oral Peptide IL-17 Antagonist Development Candidate

USD -
AED 3.6725
AFN 64.498045
ALL 82.224051
AMD 357.911109
ANG 1.790403
AOA 917.999992
ARS 1552.245042
AUD 1.487498
AWG 1.8
AZN 1.701568
BAM 1.778889
BBD 2.013452
BDT 124.862431
BGN 1.77347
BHD 0.377187
BIF 3006.125762
BMD 1
BND 1.288366
BOB 11.661285
BRL 5.778103
BSD 0.999695
BTN 93.389482
BWP 13.993424
BYN 3.000114
BYR 19600
BZD 2.010633
CAD 1.430865
CDF 2294.000592
CHF 0.840555
CLF 0.025261
CLP 994.190035
CNY 6.66615
CNH 6.66805
COP 3309.02
CRC 445.311541
CUC 1
CUP 23.992906
CVE 100.292423
CZK 22.169932
DJF 178.024567
DKK 6.80141
DOP 60.539085
DZD 137.094024
EGP 53.720858
ERN 15
ETB 164.079674
EUR 0.90995
FJD 2.297898
FKP 0.756582
GBP 0.757725
GEL 2.590255
GGP 0.756582
GHS 11.730947
GIP 0.756582
GMD 74.000173
GNF 8857.115571
GTQ 7.640288
GYD 209.05242
HKD 7.845155
HNL 26.876953
HRK 6.831965
HTG 130.972791
HUF 333.799019
IDR 18254
ILS 3.254645
IMP 0.756582
INR 93.45245
IQD 1515.562185
IRR 1929053.503608
ISK 124.48026
JEP 0.756582
JMD 158.860526
JOD 0.709026
JPY 159.414008
KES 129.990105
KGS 87.449026
KHR 4078.347196
KMF 448.000085
KPW 900.00035
KRW 1329.397181
KWD 0.31169
KYD 0.833136
KZT 443.84516
LAK 22515.803356
LBP 89525.524706
LKR 332.648142
LRD 167.946083
LSL 16.912988
LTL 2.95274
LVL 0.60489
LYD 6.460474
MAD 9.977716
MDL 18.305023
MGA 4547.687046
MKD 56.015616
MMK 2099.387164
MNT 3606.75335
MOP 8.079605
MRU 40.508252
MUR 47.860043
MVR 15.433829
MWK 1733.487348
MXN 18.45096
MYR 4.098963
MZN 63.907732
NAD 16.912757
NGN 1350.869856
NIO 36.790956
NOK 9.637045
NPR 149.424033
NZD 1.82065
OMR 0.384524
PAB 0.999682
PEN 3.414253
PGK 4.497642
PHP 63.574997
PKR 276.397058
PLN 4.00875
PYG 6228.540504
QAR 3.644326
RON 4.867103
RSD 107.038986
RUB 82.204134
RWF 1479.544504
SAR 3.760904
SBD 8.137041
SCR 13.8922
SDG 601.498572
SEK 10.13571
SGD 1.289235
SHP 0.757117
SLE 22.801691
SLL 20969.503664
SOS 571.283045
SRD 37.437963
STD 20697.981008
STN 22.283565
SVC 8.747021
SYP 13002.000337
SZL 16.91126
THB 33.8665
TJS 9.212201
TMT 3.5
TND 3.02519
TOP 2.40776
TRY 50.441697
TTD 6.768777
TWD 32.958011
TZS 2650.003017
UAH 45.318338
UGX 4148.305798
UYU 40.61103
UZS 12014.188913
VES 915.501901
VND 25687
VUV 121.064676
WST 2.823281
XAF 596.887869
XAG 0.021752
XAU 0.0002631714
XCD 2.70255
XCG 1.801703
XDR 0.707052
XOF 596.887869
XPF 108.472418
YER 236.550078
ZAR 16.95717
ZMK 9001.196037
ZMW 20.479237
ZWL 321.999592
SSP 5928.707524
MXV 2.06991
  • RIO

    -0.3300

    97.04

    -0.34%

  • CMSC

    -0.0400

    20.67

    -0.19%

  • RELX

    0.0000

    33.41

    0%

  • RBGPF

    0.0000

    67.95

    0%

  • BCE

    -0.0700

    21.99

    -0.32%

  • BCC

    -0.0300

    75.66

    -0.04%

  • GSK

    0.8600

    51.08

    +1.68%

  • JRI

    -0.0300

    11.52

    -0.26%

  • NGG

    -0.1200

    76.68

    -0.16%

  • CMSD

    0.0900

    20.54

    +0.44%

  • BTI

    -0.0800

    55.75

    -0.14%

  • AZN

    2.0200

    168.1

    +1.2%

  • BP

    -1.4200

    43.16

    -3.29%

  • RYCEF

    0.4600

    19.7

    +2.34%

  • VOD

    0.0700

    17.02

    +0.41%

Protagonist Announces Nomination of PN-881, a Potential Best-in-Class Oral Peptide IL-17 Antagonist Development Candidate
Protagonist Announces Nomination of PN-881, a Potential Best-in-Class Oral Peptide IL-17 Antagonist Development Candidate

Protagonist Announces Nomination of PN-881, a Potential Best-in-Class Oral Peptide IL-17 Antagonist Development Candidate

Oral peptide with biologics-like high potency and spectrum of activity against three therapeutically relevant dimeric forms of IL-17 (AA, AF and FF)

IND enabling studies underway, with Phase I initiation expected in Q425

Webcast and conference call to be held today at 4:30 pm ET

Text size:

Oral peptide with biologics-like high potency and spectrum of activity against three therapeutically relevant dimeric forms of IL-17 (AA, AF and FF)

IND enabling studies underway, with Phase I initiation expected in Q425

Webcast and conference call to be held today at 4:30 pm ET

Protagonist Therapeutics, Inc. ("Protagonist" or the "Company") today announced the selection of PN-881, a potential best-in-class oral peptide interleukin-17 (IL-17) antagonist, as a development candidate for the treatment of immune-mediated skin diseases.

"We are extremely pleased to nominate development candidate PN-881, a promising potential best-in-class oral peptide IL-17 antagonist that has demonstrated robust activity against all three therapeutically relevant dimeric forms of the IL-17 ligand in preclinical testing. The potency of PN-881 in our testing is orders of magnitude better than an anti-IL-17 oral small molecule analog, and better than, or on par with, various approved or developmental stage injectable antibody or nanobody therapeutic agents," said Dinesh V. Patel, PhD, President and CEO of Protagonist. "PN-881 is another example of our expertise with discovery and development of oral peptides. Earlier this week, we and our partner announced the successful outcome in two separate Phase 3 psoriasis studies with the oral peptide IL-23 receptor antagonist icotrokinra."

PN-881 has completed extensive preclinical studies, including oral stability, potency, tissue distribution, and pharmacokinetics measurements, and evaluation in immunologic pharmacodynamics and preclinical efficacy models. PN-881 has demonstrated in vitro blockade of IL-17 AA homodimer, FF homodimer and AF heterodimer. It has shown approximately 100-fold greater potency than secukinumab, and similar potency to the most potent approved antibody drugs and nanobody therapeutics in development. In multiple preclinical studies with oral dosing, PN-881 showed effective blockade in vivo of IL-17 in serum and skin and achieved preclinical proof-of-concept in a skin inflammation rodent disease model.

IND enabling studies of PN-881 are ongoing, including 7-day and 3-month toxicology studies. Planned clinical studies include a Phase 1 single ascending dose (SAD) and multiple ascending dose (MAD) study expected to begin in the fourth quarter of 2025. Results of the Phase 1 trial will inform the design and dosing in a subsequent dose-ranging psoriasis trial. Rapid expansion into other IL-17 mediated diseases, including psoriatic arthritis, hidradenitis suppurativa, and axial spondyloarthropathies, will be based on results observed in psoriasis studies.

"IL-17 and IL-23 blockers are collectively expected to lead the dermatology market, with broad opportunity for multiple indications in addition to psoriasis. An IL-17 antagonist peptide like PN-881, with best-in-class potential as an oral targeted therapy, offers an attractive therapeutic option for patients and represents another potential blockbuster drug opportunity for Protagonist," added Dr. Patel. "We look forward to progressing PN-881 rapidly into a first-in-human Phase 1 study in Q4 2025."

Conference Call and Webcast Details
The dial-in numbers for Protagonist's investor update on Thursday, November 21st at 4:30 pm ET are:

US-based Investors: 1-877-407-0752

International Investors: 1-201-389-0912

Conference Call ID: 13750274

The webcast link for the event can be found here: https://viavid.webcasts.com/starthere.jsp?ei=1698744&tp_key=f6482f31c0

A replay of the presentation will be available on the Company's Investor Relations Events and Presentations webpage following the event.

About Protagonist

Protagonist Therapeutics is a late-stage development biopharmaceutical company. Two novel peptides derived from Protagonist's proprietary discovery platform are currently in advanced Phase 3 clinical development, with New Drug Application submissions to the FDA potentially in 2025. Icotrokinra (JNJ-2113, formerly PN-235), is the first targeted oral peptide designed to selectively block the IL-23 receptor,which underpins the inflammatory response in moderate-to-severe plaque PsO and other IL-23-mediated diseases. Icotrokinra binds to the IL-23 receptor with single-digit picomolar affinity and demonstrated potent, selective inhibition of IL-23 signaling in human T cells. Icotrokinra is licensed to Johnson & Johnson (JNJ) and is currently in Phase 3 development for psoriasis and is nearing completion of Phase 2b development for ulcerative colitis. Following icotrokinra's joint discovery by Protagonist and JNJ scientists pursuant to the companies' IL-23R collaboration, Protagonist was primarily responsible for development of icotrokinra through Phase 1, with JNJ assuming responsibility for development in Phase 2 and beyond. Rusfertide, a mimetic of the natural hormone hepcidin, is currently in Phase 3 development for the rare blood disorder polycythemia vera. Rusfertide is being co-developed and will be co-commercialized with Takeda Pharmaceuticals pursuant to a worldwide collaboration and license agreement entered into in 2024 under which the Company remains primarily responsible for development through NDA filing. The Company also has a number of pre-clinical stage oral drug discovery programs addressing clinically and commercially validated targets, including IL-17 blocker PN-881, hepcidin mimetic, and anti-obesity programs.

More information on Protagonist, its pipeline drug candidates and clinical studies can be found on the Company's website at https://www.protagonist-inc.com/.

Cautionary Note on Forward-Looking Statements

This press release contains forward-looking statements for purposes of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements include statements regarding the potential benefits of PN-881, the potential market for PN-881, and the timing of PN-881 development. In some cases, you can identify these statements by forward-looking words such as "anticipate," "believe," "may," "will," "expect," or the negative or plural of these words or similar expressions. Forward-looking statements are not guarantees of future performance and are subject to risks and uncertainties that could cause actual results and events to differ materially from those anticipated, including, but not limited to, our ability to develop and commercialize our product candidates, our ability to earn milestone payments under our collaboration agreements with Janssen and Takeda, our ability to use and expand our programs to build a pipeline of product candidates, our ability to obtain and maintain regulatory approval of our product candidates, our ability to operate in a competitive industry and compete successfully against competitors that have greater resources than we do, and our ability to obtain and adequately protect intellectual property rights for our product candidates. Additional information concerning these and other risk factors affecting our business can be found in our periodic filings with the Securities and Exchange Commission, including under the heading "Risk Factors" contained in our most recently filed periodic reports on Form 10-K and Form 10-Q filed with the Securities and Exchange Commission. Forward-looking statements are not guarantees of future performance, and our actual results of operations, financial condition and liquidity, and the development of the industry in which we operate, may differ materially from the forward-looking statements contained in this press release. Any forward-looking statements that we make in this press release speak only as of the date of this press release. We assume no obligation to update our forward-looking statements, whether as a result of new information, future events or otherwise, after the date of this press release.

Investor Relations Contact
Corey Davis, Ph.D.
LifeSci Advisors
[email protected]
+1 212 915 2577

Media Relations Contact
Virginia Amann
ENTENTE Network of Companies
[email protected]
+1 833 500 0061

SOURCE: Protagonist Therapeutics

S.Jordan--TFWP